General information | |
ACovPid: | ACoVP100198 |
Trivial Name: | P4 |
Amino Acids Sequence: | PALNCYWPLNDYGFYTTSGI |
Length: | 20 |
C-Terminal Modification: | None |
N-Terminal Modification: | None |
Chemical Modification: | None |
Peptide Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
Source Description: | |
Against Virus: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
Inhibition Value Type: | IC90 |
Inhibitory Effect: | >500 |
Inhibitory Unit: | µg/mL |
Target Domain Name: | S1 domain of SARS-CoV |
Assay: | Cytopathic effect (CPE) inhibition assay |
Assay Description: | FRhK-4 cells seeded in 96-well plates were separately incubated with each peptide at a concentration of 25, 50 and 100 µg/ml starting 1 h before infection with SARS-CoV at 0.05 MOI. CPEs were determined 36 h post-infection to evaluate peptide-mediated protection from viral infection. None of the 10 peptide-treated cells exhibited cytotoxic effects at the concentrations tested. In untreated cells, the CPEs observed after 36 h were typified by cell rounding and detachment. |
Anti-CoV activity in vivo: | |
Reference: | 15918330 |
Comment: | |
3D structure: | |
Structure Experiment Verified: | NO |
Similar Peptides: | ACoVP100436   ACoVP100144   ACoVP100151    |
Target Domain information | |
Target Domain Full Name: | S1 domain of Severe acute respiratory syndrome coronavirus (SARS-CoV) spike glycoprotein |
Target Type: | glycoprotein |
UniprotID [Sequence]: | P59594 [12–672] |
Target Synonyms: | Alternative name(s) for spike glycoprotein: E2 Peplomer protein S glycoprotein |
Target Source: | Severe acute respiratory syndrome coronavirus (SARS-CoV) : 694009 |
Target Structure: | 1WNC, 1WYY, 1ZV7, 1ZV8, 1ZVB, 2AJF, 2BEQ, 2BEZ, 2DD8, 2FXP, 2GHV, 2GHW, 2RUM, 2RUN, 2RUO, 3BGF, 3D0G, 3D0H, 3D0I, 3SCI, 3SCJ, 3SCK, 3SCL, 5WRG, 5X4S, 5X58, 5X5B, 5XJK, 5XLR, 5ZVM, 6ACC, 6ACD, 6ACG, 6ACJ, 6ACK, 6CRV, 6CRW, 6CRX, 6CRZ, 6CS0, 6CS1, 6CS2, 6M3W, 6NB6, 6NB7, 6VW1, 6WAQ, 7JN5 |